What Parthenon Therapeutics does

Parthenon Therapeutics is a privately-held, early-stage biotechnology company founded in 2019 and headquartered in Cambridge, Massachusetts. The company is developing a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment, rather than directly targeting cancer cells, with the goal of addressing tumor immune evasion and immunosuppressive microenvironments that limit the effectiveness of existing cancer treatments. Its intended downstream end users are oncology healthcare providers — hospitals, cancer treatment centers, and oncology practices treating patients with solid tumors.

The company's core technology is an oncology platform built around tumor microenvironment reprogramming. No specific named product candidates, modalities (e.g., small molecule, biologic, cell therapy), or detailed platform architecture were disclosed in the available data. The differentiation strategy emphasizes a novel mechanistic angle relative to traditional targeted therapies and chemotherapy, but no patents, trademark filings, or third-party validation were surfaced.

Parthenon is pre-revenue and currently focused on research and development and clinical advancement of its programs. The company raised $65 million in Series A financing in November 2021, led by Northpond Ventures, Pfizer Venture Investments, and Taiho Ventures, with participation from Alexandria Venture Investments, Breakout Ventures, Creacion Ventures, KdT Ventures, Park West Asset Management, S32, and Tekla Capital Management. Leadership comprises co-founder and CEO Laurent Audoly, Chief Medical Officer Joseph Paul Eder, and Chief Scientific Officer Tamas Oravecz. The company employs between 11 and 50 people.

Name

Parthenon Therapeutics

Legal name

Parthenon Therapeutics

Website

https://parthenontx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Parthenon Therapeutics is a Cambridge, Massachusetts-based biotech developing a novel class of anti-cancer therapies that reprogram the tumor microenvironment. The pre-revenue company targets oncology healthcare providers treating solid tumors and is advancing its pipeline following a 2021 Series A.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Oncology drug development
• Tumor microenvironment therapy
• Anti-cancer therapeutics
• Cancer immunotherapy research
• Biotech R&D

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Drug Development Pipeline: Pre-revenue biotech company developing oncology therapeutics. Revenue model not yet established as the company is in early development stage focused on R&D and clinical advancement of its tumor microenvironment reprogramming programs.

Core offering

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment. The company is in pre-clinical/early-stage development, creating oncology programs designed to overcome tumor immune evasion and immunosuppressive tumor microenvironments that limit the effectiveness of existing cancer treatments. The company is currently pre-revenue and focused on advancing its R&D pipeline rather than commercial offerings.

Product overview

Based on available source data, Parthenon Therapeutics is a Series A-funded oncology company developing programs focused on reprogramming the tumor microenvironment. The company secured $65 million in Series A funding (2021). No specific named products, modules, or detailed product/service offerings are disclosed in the provided sources.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• Werewolf Therapeutics: Clinical-stage oncology biotech developing PREDATOR platform therapies designed to be active in the tumor microenvironment, with a similar focus on delivering immune stimulation selectively to the TME. Direct mechanistic overlap with Parthenon's TME-reprogramming approach.
• Surface Oncology: Biotech focused on immuno-oncology with multiple programs targeting the tumor microenvironment to reverse immune suppression. Highly comparable in therapeutic focus and target class to Parthenon's TME-reprogramming pipeline.
• Pyxis Oncology: Oncology biotech developing antibody-drug conjugates and immunotherapies with mechanisms that target tumor microenvironments and immune evasion pathways. Closely aligned business model and clinical focus on overcoming TME-mediated resistance.
• Compass Therapeutics: Clinical-stage biotech developing tumor-directed immunotherapies that engage both innate and adaptive immune responses within the tumor microenvironment. Comparable oncology focus and therapeutic modality profile.

Emerging players

• Obsidian Therapeutics: Developer of controllable cytokine-based immuno-oncology therapies designed to be activated specifically within the tumor microenvironment. Shares the TME-selective activation approach that underlies Parthenon's reprogramming thesis.
• Celsius Therapeutics: Single-cell genomics-driven oncology company developing therapeutics that target cellular interactions in the tumor microenvironment. Comparable early-stage, scientifically-driven oncology biotech in the TME space.
• Immuneering: Clinical-stage oncology company applying computational biology to develop novel cancer therapies, including programs aimed at TME modulation. Comparable as a small-cap, scientifically-driven oncology biotech at similar stage.

Broad incumbents

• Arcus Biosciences: Clinical-stage immuno-oncology company with multiple programs targeting adenosine pathway and other TME-mediated immune suppression mechanisms. A broader oncology portfolio player with significant overlap in TME-targeting strategy.
• Pfizer (Oncology Division): Large pharmaceutical company whose venture arm co-led Parthenon's Series A and operates a broad oncology portfolio including immune-engaging therapies. Relevant both as a strategic investor and as a benchmark for large-pharma TME programs.

Regional players

• Taiho Pharmaceutical: Japanese oncology-focused pharmaceutical company whose corporate venture arm (Taiho Ventures) co-led Parthenon's Series A. Relevant peer through shared investor relationship and overlapping focus on solid tumor therapeutics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/parthenontherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Parthenon Therapeutics